Department of Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.
Clin Infect Dis. 2022 Oct 29;75(9):1652-1654. doi: 10.1093/cid/ciac305.
We compared antibody and T-cell responses against the severe acute respiratory syndrome coronavirus 2 vaccine strain spike protein to responses against the Omicron variant in 15 messenger RNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T-cell responses.
我们比较了 15 名信使 RNA 疫苗接种者对严重急性呼吸综合征冠状病毒 2 疫苗株刺突蛋白的抗体和 T 细胞反应与对奥密克戎变异株的反应。虽然这些人对抑制奥密克戎刺突蛋白与 ACE2 结合的抗体水平明显较低，但 T 细胞反应没有差异。
